IV-01 Joomi Lee Population pharmacokinetic modeling and simulation of moxifloxacin in human aqueous humor after topical ocular application Thursday 15:20-16:40 |
IV-02 Diao Lei CD25 Occupancy by Daclizumab HYP in Patients with Relapsing Forms of Multiple Sclerosis Thursday 15:20-16:40 |
IV-03 Giulia Lestini Optimal design for informative protocols in xenograft tumor growth inhibition models Thursday 15:20-16:40 |
IV-04 Yan Li Characterization of the Oral Absorption Profiles of Sustained or Extended Release Formulations of Losartan, Dexibuprofen, Methylphenidate, and Tramadol Using Weibull Drug Release Functions Thursday 15:20-16:40 |
IV-05 Andreas Lindauer A two-part mixed-effects model for semi-continuous data to describe the effect of transdermal rotigotine on restless legs symptoms in adults Thursday 15:20-16:40 |
IV-06 Jos Lommerse Raltegravir dosing in neonates (IMPAACT P1110) – Use of allometry and maturation in PK modeling to develop a daily dosing regimen for investigation during the first weeks of life. Thursday 15:20-16:40 |
IV-07 Dominik Lott Population pharmacokinetics of the selective S1P1 receptor modulator ponesimod and its primary metabolites in healthy and organ-impaired subjects Thursday 15:20-16:40 |
IV-08 Gaohua Lu Challenges in predicting the drug-drug interaction between dextromethorphan and rifampicin using a physiologically based pharmacokinetic (PBPK) model that includes three metabolites of dextromethorphan Thursday 15:20-16:40 |
IV-09 Tong Lu Clinical Trial Simulations to Assess the Probability of Revealing Biomarker Dose-Response in Ph1 Trials Thursday 15:20-16:40 |
IV-10 Paolo Magni Evaluation of software tools for Bayesian estimation on population models with count and continuous data Thursday 15:20-16:40 |
IV-11 Mats Magnusson Population Pharmacokinetic Modeling of Paliperidone Palmitate 3-Month Formulation Thursday 15:20-16:40 |
IV-12 Adedeji Majekodunmi Impact of Hepatitis C coinfection on Immune reconstitution in HIV-infected children undergoing therapy Thursday 15:20-16:40 |
IV-13 Victor Mangas-Sanjuan Population PK Model of Lithium and Drug Compliance Assessment Thursday 15:20-16:40 |
IV-14 Alison Margolskee You can’t always get what you want: The (mis)use of deconvolution in IVIVC Thursday 15:20-16:40 |
IV-15 Eleonora Marostica Population PK/PD modelling of QT-interval prolongation in awake dogs and humans Thursday 15:20-16:40 |
IV-16 Lisa Martial Dose reduction of caspofungin in ICU patients with Child Pugh B will result in suboptimal exposure. Thursday 15:20-16:40 |
IV-17 Emma Martin Design of preclinical experiments: an example in chemotherapy-induced myelosupression Thursday 15:20-16:40 |
IV-18 David Mawdsley Model Based Network Meta-Analysis for Pharmacometrics and Drug-Development: a 3 year Research Collaboration between Pfizer and the University of Bristol. Thursday 15:20-16:40 |
IV-19 Osawa Mayu Population Pharmacokinetic Analysis of Daclatasvir and Asunaprevir in Japanese Subjects with Hepatitis C Virus infection Thursday 15:20-16:40 |
IV-20 Lynn McFadyen The Population Pharmacokinetics of Active Metabolites of a prodrug PF-0417132, (Dissociated Agonist of Glucocorticoid Receptor), in Rheumatoid Arthritis subjects Thursday 15:20-16:40 |
IV-21 Johanna Melin Population pharmacokinetic analysis of AZD4818 in healthy volunteers following three different routes of administration. Thursday 15:20-16:40 |
IV-22 Zhaoling Meng PK/PD modeling of recurrent events and clinical trial simulation in optimizing Phase 3 dose selection Thursday 15:20-16:40 |
IV-23 Enrica Mezzalana Integrating Target Mediated Drug Disposition (TMDD) into a minimal physiologically based modelling framework: evaluation of different quasi-steady-state approximations Thursday 15:20-16:40 |
IV-24 Robin Michelet Bioequivalence of desmopressin in children: a population pharmacokinetic study Thursday 15:20-16:40 |
IV-25 Iris Minichmayr Pharmacokinetic-pharmacodynamic target attainment of intravenous linezolid regimens in plasma and peripheral tissue fluids of four distinct populations Thursday 15:20-16:40 |
IV-26 Jonathan Mochel Evaluating the dose-response relationship of furosemide on diuresis and renin-angiotensin aldosterone activation in dogs combining multiple comparisons and modeling techniques Thursday 15:20-16:40 |
IV-27 Dirk Jan Moes Exploring risk factors for everolimus discontinuation and serious side effects in renal transplant recipients on everolimus and prednisolone dual therapy. Thursday 15:20-16:40 |
IV-28 Daniel Moj Is the ICRP reference man still suitable for physiologically-based pharmacokinetic (PBPK) modeling? Thursday 15:20-16:40 |
IV-30 Morris Muliaditan Determinants of variability in drug exposure and implications for dose selection in tuberculosis patients Thursday 15:20-16:40 |
IV-31 Helen Musther Extended Validation of a Peripheral Sampling Site in PBPK modelling using Clarithromycin, Dextromethorphan, Dextrorphan, Erythromycin, Lidocaine and Tramadol Thursday 15:20-16:40 |
IV-32 Efthymios Neroutsos Population pharmacokinetic study of Mycophenolic acid in patients with renal disease Thursday 15:20-16:40 |
IV-33 Ida Neldemo Assessment of the Predictive Properties of C-Reactive Protein and Interleukin 6 on Febrile Neutropenia Thursday 15:20-16:40 |
IV-34 Tram Nguyen Bayesian Fisher Information matrix for predicting estimation error and shrinkage of individual parameters with data below the quantification limit Thursday 15:20-16:40 |
IV-35 Elisabet Nielsen A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure Thursday 15:20-16:40 |
IV-37 Alanna Ocampo-Pelland Model-based Meta-analysis for Development of a Population-Pharmacokinetic (PPK) Model for Vitamin D3 and its 25OHD3 Metabolite Thursday 15:20-16:40 |
IV-38 Jaeseong Oh Population pharmacokinetic analysis of fluconazole in premature infants Thursday 15:20-16:40 |
IV-39 Andrés Olivares-Morales A reduced physiologically-based pharmacokinetic (PBPK) model for the prediction of regional gastrointestinal (GI) drug absorption Thursday 15:20-16:40 |
IV-40 Edouard Ollier Clustering Absorption Profiles of Rivaroxaban Using Between Subject Model Mixture Thursday 15:20-16:40 |
IV-41 Sean Oosterholt Population pharmacokinetics of NNZ-2566 in healthy subjects and Rett syndrome patients Thursday 15:20-16:40 |
IV-42 Fernando Ortega Modelling Amyloid- ß levels in the presence of a gamma-secretase inhibitor Thursday 15:20-16:40 |
IV-43 Aziz Ouerdani Effects of Bevacizumab and Everolimus for the treatment of Vestibular Schwannomas in patients with Neurofibromatosis Type 2 Thursday 15:20-16:40 |
IV-44 Theodoros Papathanasiou Response surface analysis of synergistic interactions of morphine and gabapentin in a rat model of postoperative pain. Thursday 15:20-16:40 |
IV-45 Wansu Park Simulation of Scanning Time Point Selection for PET Scan Studies in Clinical Development of CNS Drugs: A Simple Fixed-time Design is Recommended over Scattered-time Point Designs Thursday 15:20-16:40 |
IV-46 Gab-jin Park Drug-Drug Interaction Analysis of a Drug with Long Elimination Half-life Using Population Pharmacokinetic Approach Thursday 15:20-16:40 |
IV-47 Lorenzo Pasotti Automatic translation of Bayesian pharmacometric models: the PharmML-to-WinBugs converter Thursday 15:20-16:40 |
IV-48 Devin Pastoor Standardizing and accelerating data analysis and pharmacometric workflow with the PKPDmisc R toolkit. Thursday 15:20-16:40 |
IV-49 Eleni Pefani Drop-out estimation and PKPD analysis of a Phase 2a study for an anti-IL1R1 monoclonal antibody in Chronic Obstructive Pulmonary Disease (COPD) Thursday 15:20-16:40 |
IV-50 Sophie Peigné How modelling & simulation supported the drug development in children for a drug S Thursday 15:20-16:40 |
IV-51 Christina Pentafragka Population PK/PD modeling of granocyte colony-stimulating factors given as single and repeated doses in healthy volunteers. Thursday 15:20-16:40 |
IV-52 Jonás Samuel Pérez-Blanco Age influence on clearance of phenobarbital in paediatric patients Thursday 15:20-16:40 |
IV-53 Alejandro Pérez-Pitarch Growing evidence supporting therapeutic drug monitoring of erlotinib in non-small-cell lung cancer patients: a time-to-progression model. Thursday 15:20-16:40 |
IV-54 Carlos Perez-Ruixo Platelets dynamics in peritoneal carcinomatosis patients treated with cytoreductive surgery and hyperthermic intraperitoneal oxaliplatin Thursday 15:20-16:40 |
IV-55 Aurelie Petain Inter-species comparison of semi-physiological pre-clinical PK/PD models to better predict the time course of myelosuppression in human: application to a novel vectorized epipodophyllotoxin (F14512) Thursday 15:20-16:40 |
IV-56 Caroline Petit Designing a paediatric study for an antimalarial drug including prior information from adults Thursday 15:20-16:40 |
IV-57 Philippe Pierrillas Improvement of parameter estimations in tumor growth inhibition models on xenografted animals: a novel method to handle the interval-censoring caused by experimental measurement on smaller tumor sizes Thursday 15:20-16:40 |
IV-58 Maiara Pigatto PK/PD modeling of tumor growth inhibition after etoposide administration in vitro and to tumor-bearing rats Thursday 15:20-16:40 |
IV-59 Venkatesh Pilla Reddy Modelling and simulation of concentration-depth-time profiles in the urinary bladder wall following intravesical delivery Thursday 15:20-16:40 |
IV-60 Elodie Plan Handling Underlying Discrete Variables with Mixed Hidden Markov Models in NONMEM Thursday 15:20-16:40 |
IV-61 Daniel Polhamus Assessment of propensity score and Mahalanobis distance matching in mixed outcome data Thursday 15:20-16:40 |
IV-62 Teun Post Application of a Semi-Mechanistic, Integrated Glucose-Insulin Model to Graded Glucose Infusion Placebo Data to translate Glucose Insulin dynamics between Healthy Humans and Non-Human Primates Thursday 15:20-16:40 |
IV-63 Aurélie Premaud Mixed-effect models for longitudinal exposure to co-administered drugs and time-to-event data: prediction of risk of graft failure in renal transplant patients. Thursday 15:20-16:40 |
IV-64 Klaas Prins Acknowledging dispersion increases the power to detect central tendencies in under dispersed count data at low treatment arm size Thursday 15:20-16:40 |
IV-65 Richard Pugh The Modeling & Simulation Workbench – Enabling Model-Based Decisions in Drug Development Thursday 15:20-16:40 |
IV-66 Didier Renard Modeling of pharmacokinetic data using nonlinear mixed-effects: a paradigm shift in veterinary pharmacology. A case study with the nonsteroidal anti-inflammatory robenacoxib in cats Thursday 15:20-16:40 |
IV-67 Su-jin Rhee A population pharmacokinetic analysis of once-daily intravenous busulfan in pediatric patients undergoing hematopoietic stem cell transplantation Thursday 15:20-16:40 |
IV-68 Marie-Karelle Riviere-Jourdan Evaluation of the expected Fisher information matrix without linearization, in nonlinear mixed effect models for discrete and continuous outcomes Thursday 15:20-16:40 |
IV-69 Dirk Garmann RTTE analysis of repeated bleeding events in haemophilia A after recombinant factor VIII treatment Thursday 15:20-16:40 |
IV-70 Leire Ruiz Cerdá Systems Pharmacology Model of the Co-stimulation Process of Immune Response in Systemic Lupus Erythematosus. Thursday 15:20-16:40 |
IV-71 Alberto Russu Modelling pharmacokinetics and CSF Abeta1-40 reduction in humans after dosing with JNJ-54861911, a novel oral BACE inhibitor Thursday 15:20-16:40 |
IV-72 Yevgen Ryeznik Adaptive designs for dose finding clinical trials with time-to-event outcomes Thursday 15:20-16:40 |
IV-73 Muhammad Waqas Sadiq A whole-body physiologically based pharmacokinetic (WBPBPK) model of ciprofloxacin for prediction of bacterial killing at the site of infection Thursday 15:20-16:40 |
IV-74 Tarjinder Sahota Efficient argument settings for NONMEM 7 expectation maximisation methods Thursday 15:20-16:40 |
IV-75 Maria Luisa Sardu Xenograft experiments: assessing consistency between a drug-driven and a biomarker-driven tumor growth inhibition model Thursday 15:20-16:40 |
IV-77 Franziska Schädeli Stark Use of PBPK information to select the doses and criteria for early dose confirmation or adjustment with a minimum number of subjects in a pediatric proof of concept (POC) study Thursday 15:20-16:40 |